Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Research and Development Expenses: $14.6 million in Q3 2024, down from $18.2 million in Q3 2023. General and Administrative Expenses: $8.4 million in Q3 2024, down from $10 million in Q3 2023. Net Loss: $21.7 million in Q3 2024, compared to $24 million in Q3 2023. Cash Guidance: Expected to end 2024 with approximately $240 million in cash, cash equivalents, and marketable securities. Cash Burn 2025: Projected to be approximately $55 million to $65 million. Funding Sufficiency: Existing cash expected to fund operations into at least 2027. Warning! GuruFocus has detected 2 Warning Signs with FULC. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Fulcrum Therapeutics Inc ( NASDAQ:FULC ) has a strong cash position with $257.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024. The company is advancing its pociredir program, an oral HbF inducer, for the
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.MarketBeat
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024GlobeNewswire
- Fulcrum Therapeutics to Participate in the Stifel Healthcare ConferenceGlobeNewswire
FULC
Earnings
- 11/13/24 - Beat
FULC
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/14/24 - Form 4
- FULC's page on the SEC website